# TARGET Study: Safety and Performance of the Cardiovalve TR Replacement System

Study · id `cardio:ct-nct05486832` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05486832](<https://clinicaltrials.gov/study/NCT05486832>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05486832

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 157 participants.

## Technical summary

Registry record NCT05486832. Allocation not applicable; no masking; primary purpose treatment. Start 2022-12-09 (actual); primary completion 2026-03-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 157 participants (enrolled count; ClinicalTrials.gov record NCT05486832, source copy `cardio:ctgov-nct05486832-2026-05-11`, retrieved 2026-10-26)
- Started: 2022-12-09 (actual) (ClinicalTrials.gov record NCT05486832, source copy `cardio:ctgov-nct05486832-2026-05-11`, retrieved 2026-10-26)
- Primary completion: 2026-03-15 (actual) (ClinicalTrials.gov record NCT05486832, source copy `cardio:ctgov-nct05486832-2026-05-11`, retrieved 2026-10-26)
- Completion: 2031-12-15 (anticipated) (ClinicalTrials.gov record NCT05486832, source copy `cardio:ctgov-nct05486832-2026-05-11`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT05486832, source copy `cardio:ctgov-nct05486832-2026-05-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05486832-2026-05-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: TARGET Study: Safety and Performance of the Cardiovalve TR Replacement System
- Acronym: TARGET
- Condition: Tricuspid Regurgitation
- Intervention (Device): Cardiovalve TR valve replacement System
- Lead sponsor: Cardiovalve Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Tricuspid regurgitation (`cardio:tricuspid-regurgitation`)

## Provenance

Content hash: e030b9a7603dfdc5f1c819921d4c39fcd3884036b7984043c60e256c3045727d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
